Video

Dr. Antonarakis on the Utility of Sipuleucel-T Plus Radium-223 in Nonmetastatic CRPC

Emmanuel S. Antonarakis, MBBCh, discusses the utility of sipuleucel-T plus radium-223 in nonmetastatic castration-resistant prostate cancer.

Emmanuel S. Antonarakis, MBBCh, professor of oncology, Johns Hopkins Medicine, discusses the utility of sipuleucel-T (Provenge) plus radium-223 (Xofigo) in nonmetastatic castration-resistant prostate cancer (CRPC).

Radium-223 is a bone-targeting radiopharmaceutical that emits an alpha particle, says Antonarakis.

As such, it is not likely to have efficacy in patients with nonmetastatic CRPC or rising prostate-specific antigen who do not have bone metastases, explains Antonarakis.

Sipuleucel-T is currently approved in metastatic CRPC. It is unknown whether sipuleucel-T and radium-223 can prevent bone metastases in patients with nonmetastatic CRPC. However, without a target, a drug like radium-223 may not be effective, concludes Antonarakis.

Related Videos
Aditya Bardia, MD, MPH, FASCO
Christina S. Baik, MD, MPH
Dana Zakalik, MD
David C. Fisher, MD
Kevin Kalinsky, MD, MS
Alberto Montero, MD, MBA, CPHQ
R. Lor Randall, MD, FACS
Daniel E. Haggstrom, MD
Jairam Krishnamurthy, MD, FACP
Yair Lotan, MD, professor, urology, chief, urologic oncology, Jane and John Justin Distinguished Chair in Urology, UT Southwestern Harold C. Simmons Comprehensive Cancer Center; medical director, Urology Clinic, UT Southwestern and Parkland Health and Hospital System